Cannabis use in pregnancy and breastfeeding: The pharmacist's role.
Journal
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
ISSN: 1715-1635
Titre abrégé: Can Pharm J (Ott)
Pays: United States
ID NLM: 101257110
Informations de publication
Date de publication:
Historique:
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
epublish
Résumé
The recent legalization of cannabis use in Canada requires pharmacists to be able to support their patients with accurate knowledge of its known risks and benefits. Certain populations, such as pregnant and breastfeeding women and their developing children, may be at higher risk than other populations. The authors independently searched the literature for clinical reports or reviews of the literature regarding the safety of cannabis use in pregnancy and breastfeeding using search terms such as This review combines the relevant pharmacological, pharmacokinetic and clinical evidence for the effects of cannabis in this special patient population. The literature demonstrates that some of the constituents of cannabis can reach children in utero and through breastmilk. Given that Δ⁹-tetrahydrocannabinol can be present in breastmilk as quickly as 1 hour after consumption and last up to 6 days, it may not be possible to use cannabis and avoid infant exposure. There is evidence that this exposure may result in cognitive, social and motor defects. Some of these effects may be long term, lasting years. The pharmacist must be able to educate and screen patients regarding marijuana use in pregnancy and breastfeeding, with the ultimate aim of harm reduction.
Sections du résumé
BACKGROUND
BACKGROUND
The recent legalization of cannabis use in Canada requires pharmacists to be able to support their patients with accurate knowledge of its known risks and benefits. Certain populations, such as pregnant and breastfeeding women and their developing children, may be at higher risk than other populations.
METHODS
METHODS
The authors independently searched the literature for clinical reports or reviews of the literature regarding the safety of cannabis use in pregnancy and breastfeeding using search terms such as
RESULTS
RESULTS
This review combines the relevant pharmacological, pharmacokinetic and clinical evidence for the effects of cannabis in this special patient population. The literature demonstrates that some of the constituents of cannabis can reach children in utero and through breastmilk. Given that Δ⁹-tetrahydrocannabinol can be present in breastmilk as quickly as 1 hour after consumption and last up to 6 days, it may not be possible to use cannabis and avoid infant exposure. There is evidence that this exposure may result in cognitive, social and motor defects. Some of these effects may be long term, lasting years. The pharmacist must be able to educate and screen patients regarding marijuana use in pregnancy and breastfeeding, with the ultimate aim of harm reduction.
Identifiants
pubmed: 32206154
doi: 10.1177/1715163519893395
pii: 10.1177_1715163519893395
pmc: PMC7079319
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
95-100Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Conflict of Interest:None of the authors have any conflicts to declare.
Références
J Pediatr. 2018 Jun;197:90-96
pubmed: 29605394
Obstet Gynecol. 2018 May;131(5):783-788
pubmed: 29630019
PLoS One. 2012;7(7):e39154
pubmed: 22815699
Chem Biodivers. 2007 Aug;4(8):1770-804
pubmed: 17712819
Am J Obstet Gynecol. 2017 Dec;217(6):705-707
pubmed: 28843740
BMJ Open. 2016 Apr 05;6(4):e009986
pubmed: 27048634
Neurotoxicol Teratol. 1988 Jul-Aug;10(4):305-13
pubmed: 3226373
Am J Obstet Gynecol. 2016 Oct;215(4):506.e1-7
pubmed: 27263998
N Engl J Med. 1982 Sep 23;307(13):819-20
pubmed: 6287261
J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1173-81
pubmed: 19858757
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:45-52
pubmed: 24075896
J Addict Med. 2017 May/Jun;11(3):211-216
pubmed: 28252456
Eur J Intern Med. 2018 Mar;49:12-19
pubmed: 29307505
NIDA Res Monogr. 1985;59:48-60
pubmed: 3929132
Clin Pharmacol Ther. 1980 Sep;28(3):409-16
pubmed: 6250760
Reprod Toxicol. 2016 Jul;62:77-86
pubmed: 27142189
Pediatrics. 2018 Sep;142(3):
pubmed: 30150209
Drug Alcohol Depend. 2011 Nov 1;118(2-3):470-4
pubmed: 21470799
Pain Res Manag. 2005 Autumn;10 Suppl A:15A-22A
pubmed: 16237477
Breastfeed Med. 2015 Sep;10(7):377-80
pubmed: 26252053
Front Psychiatry. 2013 Oct 14;4:129
pubmed: 24133461
Pediatrics. 2018 Sep;142(3):
pubmed: 30150212
Obstet Gynecol. 2016 Oct;128(4):713-23
pubmed: 27607879
Obstet Gynecol. 2018 Nov;132(5):1198-1210
pubmed: 30234728
Neurotoxicol Teratol. 2000 May-Jun;22(3):325-36
pubmed: 10840176
Ann Pharmacother. 2003 Sep;37(9):1299-306
pubmed: 12921514
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
BJOG. 2014 Jul;121(8):971-7
pubmed: 24621183
Neurotoxicol Teratol. 1990 Mar-Apr;12(2):161-8
pubmed: 2333069
CMAJ Open. 2017 Jun 26;5(2):E517-E523
pubmed: 28655728
Obstet Gynecol. 2018 Jun;131(6):1031-1038
pubmed: 29742676